Hiemstra B, et al. - Following The Cochrane Handbook for Systematic Reviews of Interventions, researchers performed this systematic review to evaluate the impacts of dopamine in critically ill patients with cardiac dysfunction. They analyzed 17 trials, including 1,218 patients, published until April 19, 2018. They also carried out Trial Sequential Analyses and assessed bias risk. All-cause mortality at longest follow-up was considered as primary outcome and serious adverse events, myocardial infarction, arrhythmias, and renal replacement therapy were assessed as secondary outcomes. Findings revealed no significant association of dopamine vs any control treatment, with relative risk of mortality or any other patient-centered outcomes. By the Trial Sequential Analyses, the information was insufficient, so the anticipated intervention impacts were neither confirmed nor rejected. Overall, sparse, low quality, and inconclusive evidence was found for dopamine in critically ill patients with cardiac dysfunction. Dopamine use for cardiac dysfunction could neither be recommended nor refuted.